On Track to Profitability, Price Target Increased (MST), page-160

Also an important note on why it is so important to ignore the noise and back your calls:


Also to all the holders, not worth engaging with the trolls and the "what if” clowns. We know that this is an excellent company that has been performing incredibly well, the new device is an absolute hit in the ophthalmology community and all the doctors are clearly rushing to try it out. Of course there will always be risks for any investment, but an almost $40m market cap the valuation is MORE than accounting for these risks. As long as the company continues to improve fundamentally, its day in the spotlight is inevitable. In the meantime, enjoy the buying opportunities from the sheep who don't know how to analyse a company and simply follow the market.